CN116270489A - Ginger stomach-activating granule and preparation method thereof - Google Patents
Ginger stomach-activating granule and preparation method thereof Download PDFInfo
- Publication number
- CN116270489A CN116270489A CN202310285253.7A CN202310285253A CN116270489A CN 116270489 A CN116270489 A CN 116270489A CN 202310285253 A CN202310285253 A CN 202310285253A CN 116270489 A CN116270489 A CN 116270489A
- Authority
- CN
- China
- Prior art keywords
- preparation
- water
- fructus
- volatile oil
- gongwei
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/754—Evodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention provides ginger stomach-activating granules and a preparation method thereof. The Jiang Gongwei A granule comprises fructus Litseae Pungentis, mahonia, rhizoma corydalis, radix Cynanchi Paniculati, fructus evodiae, and pericarpium Citri Tangerinae; the preparation method comprises the following steps: (1) extracting volatile oil; (2) water extraction; (3) purifying; (4) concentrating; and (5) forming the preparation. The method improves the prior process, strengthens the curative effect of the preparation, improves the quality of the preparation, has good thawing property, high clarity after brewing, good taste, high patient compliance, no adverse reaction and safe medication. Is a very successful preparation in hospital and has the value of deep development and utilization.
Description
Technical Field
The invention belongs to the technical field of medicines, and in particular relates to ginger stomach-invigorating granules and a preparation method thereof.
Background
Reflux esophagitis (reflux esophagitis, RE) is a common clinical manifestation of gastroesophageal reflux disease (GERD), accounting for about 48% -79% of patients with gastroesophageal reflux disease. Epidemiologists have investigated that the incidence of GERD in our country is 5.77% and the incidence of RE is 1.92%. RE is a symptom or tissue damage caused by reflux of stomach or duodenal contents into the esophagus, and clinical manifestations are mainly acid regurgitation, heartburn, poststernal pain, and dysphagia in severe cases. The main medicines for treating reflux esophagitis by Western medicine currently take various Proton Pump Inhibitors (PPIs) as main flows, and the medicines have quick clinical effect and good acid production effect, but are required to be taken for a long time, cannot be radically treated, have high treatment cost, have heavy economic burden on patients, and can present a potential risk factor which cannot be ignored if being continuously used for a long time.
Studies have shown that: PPIs can affect the biological barrier of the gut by altering its normal flora, increasing the risk of intestinal infections and the application of PPIs can cause calcium ion malabsorption. It has been reported that 2 patients with long-term PPI developed digestive tract carcinoid tumors, and the analysis led to the conclusion that: the hypergastrinopathy induced by PPI application may cause intestinal epithelioid carcinoid tumors.
The traditional Chinese medicine has good clinical curative effects of high effective rate and low recurrence rate in treating reflux esophagitis. For example, li Guohong "Hedychium soup for 50 cases of clinical study on reflux esophagitis", yang Liping "Zhuji soup for 120 cases of clinical observation on reflux esophagitis", li Qiong "Wei Anliu He soup for 18 cases of stomach ache" and so on. The traditional Chinese medicine for treating reflux esophagitis can relieve the pain of patients caused by long-term proton pump acid preparation, can also relieve the economic burden of the patients, has no traditional Chinese medicine preparation for treating reflux esophagitis at present in China, and has great significance in developing the traditional Chinese medicine preparation effective for reflux esophagitis on the basis of a clinical effective proved recipe.
Jiang Gongwei A granule is an intra-hospital preparation for clinically treating reflux esophagitis in a long term in China, and the preparation has been used in China for 6 years, and has obvious treatment effect on more than thousands of patients. The preparation formula comprises the following components: 200g of fructus litsea, 200g of Chinese mahonia, 150g of rhizoma corydalis, 150g of radix cynanchi wilfordii, 100g of fructus evodiae and 100g of dried orange peel, wherein the preparation amount is 1000g, the specification is 10g per bag, and 1 bag is taken each time, and 3 times per day.
The original preparation process of Jiang Gongwei A granules comprises the following steps: decocting the prescription Chinese medicinal materials with water for 2 times and 1 hr each time, concentrating the filtrate into soft extract, adding appropriate amount of soluble starch, and making into 1000g granule.
Jiang Gongwei A granule has definite clinical curative effect, and the fact that doctors and patients are fully affirmed fully proves that Jiang Gongwei A granule is a very successful hospital preparation and has the value of advanced development and utilization. The Jiang Gongwei A granule can be obtained by carrying out demonstration analysis on the prescription and the preparation process of the Jiang Gongwei A granule, so that the aim of improving quality and enhancing efficiency is fulfilled.
Disclosure of Invention
The invention aims to provide ginger stomach-activating granules;
the invention aims to provide a preparation method of ginger stomach-activating granules.
The invention is realized by the following technical scheme:
the Jiang Gongwei A granule consists of the following components in parts by weight: 180-220g of fructus alpiniae oxyphyllae, 180-220g of Chinese mahonia, 136-164g of rhizoma corydalis, 136-164g of radix cynanchi wilfordii, 94-106g of fructus evodiae and 94-106g of dried orange peel.
Preferably, the Jiang Gongwei A granule provided by the invention comprises the following components in parts by weight: 190-210g of fructus alpiniae oxyphyllae, 190-210g of Chinese mahonia, 143-157g of rhizoma corydalis, 143-157g of radix cynanchi wilfordii, 97-103g of fructus evodiae and 97-103g of dried orange peel.
Further preferably, the Jiang Gongwei A granule provided by the invention comprises the following components in parts by weight: 200g of fructus litsea, 200g of Chinese mahonia, 150g of rhizoma corydalis, 150g of radix cynanchi wilfordii, 100g of fructus evodiae and 100g of dried orange peel.
The preparation method of Jiang Gongwei A particles comprises the following steps:
(1) Extracting volatile oil: weighing fructus Litseae Pungentis and pericarpium Citri Tangerinae according to the proportion, adding 4-8 times of water, distilling and extracting for 1-3 hr, receiving distillate, standing to obtain volatile oil; filtering the water solution, and reserving filtrate;
(2) Water extraction: weighing Chinese mahonia, rhizoma corydalis, radix cynanchi wilfordii and fructus evodiae according to the prescription proportion, adding the Chinese mahonia, rhizoma dioscoreae nipponicae and fructus evodiae after distillation into the residue of the fructus litsea coreae and pericarpium citri reticulatae, adding water for decocting for 1-2 times, adding 3-6 times of water for each time for 1-2 hours, filtering, combining the filtrates, and concentrating under reduced pressure to obtain a clear paste with the relative density of 1.05-1.15, wherein each 1mL corresponds to 1g-2g of medicinal materials;
(3) Purifying: adding 2% -4% ZTC clarifier B solution into the fluid extract, stirring, maintaining at 40-60deg.C for 20-40min, then adding 1% -2% ZTC clarifier A solution, maintaining at 40-60deg.C for 20-40min, standing for 12-48 hr, filtering, and keeping filtrate for use;
(4) Concentrating: concentrating the filtrate under reduced pressure to obtain soft extract with relative density of 1.10-1.20;
(5) And (3) preparation molding: directly adding appropriate amount of soluble starch and 10g of aspartame into the thick paste, granulating, drying, spraying volatile oil, stewing thoroughly, and granulating to obtain 1000g of granule.
Preferably, in the step (1) of the invention, 5 times of water is added, and the distillation extraction is carried out for 3 hours.
Preferably, in the step (2), water is added for 2 times, each time for 1 hour, and each time, 6 times of water is added.
The relative density in step (2) of the present invention is preferably 1.10.
Preferably, 3% of ZTC clarifying agent B solution is added into the fluid extract in the step (3), stirring is carried out, the temperature is kept at 40 ℃ for 30min, then 1.5% of ZTC clarifying agent A solution is added, the temperature is kept at 40 ℃ for 20min, and the mixture is kept for 12h.
The conditions of the reduced pressure concentration in the step (2) and the step (4) are as follows: the temperature is 75-85 ℃, and the pressure is-0.05 to-0.09 Mpa.
Preferably, the conditions of the reduced pressure concentration in the step (2) and the step (4) are as follows: the temperature is 80 ℃, and the pressure is-0.06 to-0.08 Mpa.
The invention has the beneficial effects that:
1. improving the extraction process and enhancing the curative effect of the preparation. The original preparation process does not extract volatile oil, and the improved process not only extracts the volatile oil, but also formulates detailed volatile oil extraction process parameters through experimental study, thereby being convenient for production operation; clinical comparative experiments of the preparation of the two processes before and after improvement show that the total effective rate of the preparation curative effect is increased by 9% after the volatile oil is added.
2. The purification process is added, and the quality of the preparation is improved. The original preparation process has no purification process, and the particles are more suspended matters after melting and have poor taste; the improved process not only increases the purification process, but also establishes detailed purification process parameters through experimental study, thereby being convenient for production operation; the preparation after the purification process is added has good thawing property, high clarity after brewing, good taste and high patient compliance.
3. The invention researches the extraction method of the volatile oil through experiments, and the method is as follows: extracting by direct distillation, adding 5 times of water, and distilling for 3 hr to obtain volatile oil with better quality.
4. The invention researches the water extraction process by combining an orthogonal test and a comprehensive evaluation method, and the method is characterized in that: under the optimal technological conditions of adding 6 times of water and decocting for 2 times and 1 hour each time, the extraction rate and the dry extract yield of the berberine hydrochloride are the best.
5. The invention adopts two different methods, namely a water extraction and alcohol precipitation method and a ZTC clarifier purification method to study the purification process, and combines an orthogonal test and a comprehensive evaluation method to obtain the water extraction and alcohol precipitation type purification agent: (1) The ZTC clarifier has more ideal impurity removal effect, and the clarifier is obviously superior to an alcohol precipitation method in both the retention rate of active ingredients and the impurity removal rate; (2) The clarifier purification method comprises concentrating the extractive solution to relative density of 1.10, adding 3% ZTC clarifier B solution, maintaining at 40deg.C for 30min, then adding 1.5% ZTC clarifier A solution, and maintaining at 40deg.C for 20min under optimal process conditions to obtain berberine hydrochloride with optimal extraction rate, impurity removal rate and comprehensive score.
6. The invention adopts two different methods of normal pressure concentration and reduced pressure concentration to examine the water extract, and evaluates the concentration effect by taking the total amount of berberine hydrochloride in the thick extract, the color of the extract and the concentration time as indexes, thereby obtaining the following components: the concentration mode has no obvious influence on the berberine hydrochloride content in the extract, the color of the extract is not different, the reduced pressure concentration time is relatively short, and finally, the preferred concentration mode is reduced pressure concentration, so that the concentration efficiency is improved, and the cost is saved.
7. The clinical curative effect verification shows that the invention has the following advantages: the total effective rate of clinical curative effect of the preparation produced by adopting the improved process of Jiang Gongwei A granules is improved by 9% compared with that of the original process, and the aim of improving quality and enhancing efficiency is achieved after the process is improved, so that adverse reaction is avoided, and the medicine is safe to use.
Detailed Description
Example 1 Jiang Gongwei an granules
The composition is as follows: 200g of fructus litsea, 200g of Chinese mahonia, 150g of rhizoma corydalis, 150g of radix cynanchi wilfordii, 100g of fructus evodiae and 100g of dried orange peel.
Example 2 Jiang Gongwei an granules
The composition is as follows: 180g of fructus litsea, 180g of Chinese mahonia, 164g of rhizoma corydalis, 164g of radix cynanchi wilfordii, 106g of fructus evodiae and 106g of pericarpium citri reticulatae.
Example 3 Jiang Gongwei an granules
The composition is as follows: 220g of fructus trichosanthis, 220g of Chinese mahonia, 136g of rhizoma corydalis, 136g of radix cynanchi wilfordii, 94g of fructus evodiae and 94g of dried orange peel.
Example 4 Jiang Gongwei an granules
The composition is as follows: 215g of fructus litsea, 215g of Chinese mahonia, 139g of rhizoma corydalis, 139g of radix cynanchi wilfordii, 96g of fructus evodiae and 96g of dried orange peel.
Example 5 Jiang Gongwei an granules
The composition is as follows: 210g of fructus litsea, 210g of Chinese mahonia, 142g of rhizoma corydalis, 142g of radix cynanchi wilfordii, 98g of fructus evodiae and 98g of dried orange peel.
Example 6 Jiang Gongwei an granules
The composition is as follows: 205g of fructus litsea coreana, 205g of Chinese mahonia, 145g of rhizoma corydalis, 145g of radix cynanchi wilfordii, 100g of fructus evodiae and 100g of pericarpium citri reticulatae.
Example 7 Jiang Gongwei an granules
The composition is as follows: 200g of fructus litsea, 200g of Chinese mahonia, 148g of rhizoma corydalis, 148g of radix cynanchi wilfordii, 102g of fructus evodiae and 102g of dried orange peel.
Example 8 Jiang Gongwei an granules
The composition is as follows: 195g of fructus trichosanthis, 195g of Chinese mahonia, 151g of rhizoma corydalis, 151g of radix cynanchi wilfordii, 104g of fructus evodiae and 104g of dried orange peel.
Example 9 Jiang Gongwei an granules
The composition is as follows: 190g of fructus trichosanthis, 190g of Chinese mahonia, 154g of rhizoma corydalis, 154g of radix cynanchi wilfordii, 106g of fructus evodiae and 106g of dried orange peel.
Example 10 Jiang Gongwei an granules
The composition is as follows: 185g of fructus trichosanthis, 185g of Chinese mahonia, 163g of rhizoma corydalis, 163g of radix cynanchi wilfordii, 102g of fructus evodiae and 102g of dried orange peel.
The compositions of examples 1-10 are used in the following examples
Example 11 preparation of Jiang Gongwei an granules
(1) Extracting volatile oil: weighing fructus Litseae Pungentis and pericarpium Citri Tangerinae according to the proportion, adding 5 times of water, distilling and extracting for 3 hr, receiving distillate, standing to obtain volatile oil; filtering the water solution, and reserving filtrate;
(2) Water extraction: weighing Chinese mahonia, rhizoma corydalis, radix cynanchi wilfordii and fructus evodiae according to the prescription proportion, adding the Chinese mahonia, rhizoma dioscoreae nipponicae and fructus evodiae after distillation into the residues of the fructus litsea coreae and pericarpium citri reticulatae, adding water for 2 times, adding 6 times of water each time for 1 hour, filtering, combining the filtrates, and concentrating under reduced pressure to obtain a clear paste with the concentration of 1g-2g of medicinal materials each 1 mL;
(3) Purifying: adding 3% ZTC clarifier B solution into the fluid extract, stirring, maintaining at 40deg.C for 30min, adding 1.5% ZTC clarifier A solution, maintaining at 40deg.C for 20min, standing for 12 hr, and filtering to obtain filtrate;
(4) Concentrating: concentrating the filtrate under reduced pressure to obtain soft extract with relative density of 1.10-1.20;
(5) And (3) preparation molding: directly adding appropriate amount of soluble starch and 10g of aspartame into the thick paste, granulating, drying, spraying volatile oil, stewing thoroughly, and granulating to obtain 1000g of granule.
Example 12 preparation of Jiang Gongwei An particles
(1) Extracting volatile oil: weighing fructus Litseae Pungentis and pericarpium Citri Tangerinae according to the proportion, adding 4 times of water, distilling and extracting for 1 hr, receiving distillate, standing to obtain volatile oil; filtering the water solution, and reserving filtrate;
(2) Water extraction: weighing Chinese mahonia, rhizoma corydalis, radix cynanchi wilfordii and fructus evodiae according to the prescription proportion, adding distilled fructus litsea coreana and pericarpium citri reticulatae dreg, adding 3 times of water, decocting for 1 time, decocting for 1 hour, filtering, and concentrating the filtrate under reduced pressure to obtain fluid extract of 1-2 g medicinal materials per 1 mL;
(3) Purifying: adding 2% ZTC clarifier B solution into the fluid extract, stirring, maintaining at 40deg.C for 20min, adding 1% ZTC clarifier A solution, maintaining at 40deg.C for 20min, standing for 12 hr, and filtering to obtain filtrate;
(4) Concentrating: concentrating the filtrate under reduced pressure to obtain soft extract with relative density of 1.10-1.20;
(5) And (3) preparation molding: directly adding appropriate amount of soluble starch and 10g of aspartame into the thick paste, granulating, drying, spraying volatile oil, stewing thoroughly, and granulating to obtain 1000g of granule.
Example 13 preparation of Jiang Gongwei An particles
(1) Extracting volatile oil: weighing fructus Litseae Pungentis and pericarpium Citri Tangerinae according to the proportion, adding 8 times of water, distilling and extracting for 3 hr, receiving distillate, standing to obtain volatile oil; filtering the water solution, and reserving filtrate;
(2) Water extraction: weighing Chinese mahonia, rhizoma corydalis, radix cynanchi wilfordii and fructus evodiae according to the prescription proportion, adding the Chinese mahonia, rhizoma dioscoreae nipponicae and fructus evodiae after distillation into the residues of the fructus litsea coreae and pericarpium citri reticulatae, adding water for 2 times, adding 6 times of water each time for 2 hours, filtering, combining the filtrates, and concentrating under reduced pressure to obtain a clear paste with the concentration of 1g-2g of medicinal materials each 1 mL;
(3) Purifying: adding 4% ZTC clarifier B solution into the fluid extract, stirring, maintaining at 60deg.C for 40min, then adding 2% ZTC clarifier A solution, maintaining at 60deg.C for 40min, standing for 48 hr, and filtering to obtain filtrate;
(4) Concentrating: concentrating the filtrate under reduced pressure to obtain soft extract with relative density of 1.10-1.20;
(5) And (3) preparation molding: directly adding appropriate amount of soluble starch and 10g of aspartame into the thick paste, granulating, drying, spraying volatile oil, stewing thoroughly, and granulating to obtain 1000g of granule.
Example 14 preparation of Jiang Gongwei an granules
(1) Extracting volatile oil: weighing fructus Litseae Pungentis and pericarpium Citri Tangerinae according to the proportion, adding 6 times of water, distilling and extracting for 2 hr, receiving distillate, standing to obtain volatile oil; filtering the water solution, and reserving filtrate;
(2) Water extraction: weighing Chinese mahonia, rhizoma corydalis, radix cynanchi wilfordii and fructus evodiae according to the prescription proportion, adding the Chinese mahonia, rhizoma dioscoreae nipponicae and fructus evodiae after distillation into the residues of the fructus litsea coreae and pericarpium citri reticulatae, adding water for 2 times, adding 4 times of water each time for 2 hours, filtering, combining the filtrates, and concentrating under reduced pressure to obtain a clear paste with the concentration of 1-2 g of medicinal materials each 1 mL;
(3) Purifying: adding 3.5% ZTC clarifier B solution into the fluid extract, stirring, maintaining at 60deg.C for 40min, adding 1.5% ZTC clarifier A solution, maintaining at 60deg.C for 40min, standing for 48 hr, and filtering to obtain filtrate;
(4) Concentrating: concentrating the filtrate under reduced pressure to obtain soft extract with relative density of 1.10-1.20;
(5) And (3) preparation molding: directly adding appropriate amount of soluble starch and 10g of aspartame into the thick paste, granulating, drying, spraying volatile oil, stewing thoroughly, and granulating to obtain 1000g of granule.
To further verify the feasibility of the invention, the inventors performed a series of experiments, specifically as follows:
1. jiang Gongwei An granule preparation process fumbling test
1.1 formulation prescription
200g of fructus litsea, 200g of Chinese mahonia, 150g of rhizoma corydalis, 150g of radix cynanchi wilfordii, 100g of fructus evodiae and 100g of dried orange peel;
the litsea coreana is a monarch drug in the prescription, is rich in volatile oil, has the volatile oil content of more than 3 percent, and is proved by modern pharmacological research to have good analgesic and anti-inflammatory effects and be a material basis for the prescription to exert the drug effect. In addition, the pericarpium citri reticulatae also contains volatile oil in the prescription, and the volatile oil also has the effects of promoting qi circulation and diminishing inflammation. The Jiang Gongwei A granule original preparation process only keeps water-soluble components in the prescription, and does not extract volatile oil, the process is obviously unreasonable, and the volatile oil of the pungent litse fruit and the dried orange peel in the prescription is extracted from the view point of enhancing the curative effect and added into the preparation.
1.2 preparation Process
1.2.1 the volatile oil extraction Process is preferred
The fruit of litsea coreana and dried orange peel in the prescription are rich in volatile oil, and modern researches show that the volatile oil of the fruit of litsea coreana and dried orange peel has stronger qi-moving and pain-relieving effects, and is a material basis for the prescription to play a role in treatment. The invention establishes the extraction method of the volatile oil through experimental study, extracts the volatile oil of the litsea coreana and the dried orange peel in the prescription, and adds the volatile oil into the preparation to play a role in enhancing the clinical effect.
1.2.1.1 investigation of the Water addition
Weighing 100g of litsea coreana and 50g of dried orange peel, uniformly mixing, taking three parts, respectively adding 4 times of water, 5 times of water and 6 times of water, distilling and extracting volatile oil, respectively extracting for 4 hours, receiving distillate, washing the inner wall of a condensing tube and a volatile oil extractor by petroleum ether, combining the petroleum ether liquid and the oil-water liquid, extracting by petroleum ether for three times, 15ml each time, combining the petroleum ether liquid, dehydrating and filtering by anhydrous sodium sulfate, washing a funnel by 10ml of petroleum ether, volatilizing petroleum ether to constant weight at low temperature, and weighing the weight of the volatile oil to obtain the compound. The results are shown in Table 1.
TABLE 1 investigation of the water addition
The test result shows that the amount of the volatile oil obtained by adding 4 times of water is lower; the amount of the volatile oil obtained by adding 5 times of water is basically equivalent to that of the volatile oil obtained by adding 6 times of water, and the amounts of the volatile oil and the water are more than 4 times of that of the volatile oil. Therefore, the water addition amount was finally determined to be 5 times.
1.2.1.2 pretreatment modes
Weighing 100g of litsea coreana and 50g of dried orange peel, uniformly mixing, taking three parts, adding 5 times of water into each part, directly distilling and extracting volatile oil for 4 hours in the first part, cold soaking for 1 hour in the second part, distilling and extracting volatile oil for 4 hours in the second part, heating to 80 ℃ for 1 hour in the third part, distilling and extracting volatile oil for 4 hours, respectively receiving distillate, washing a condensing tube and the inner wall of a volatile oil extractor by petroleum ether, combining the petroleum ether liquid and the oil-water liquid, extracting by petroleum ether three times, 15ml each time, combining the petroleum ether liquid, dehydrating and filtering by anhydrous sodium sulfate, washing a funnel by 10ml of petroleum ether, volatilizing petroleum ether at low temperature to constant weight, and weighing the weight of the volatile oil to obtain the compound oil; collecting the volatile oil in another container. The results are shown in Table 2.
Table 2 investigation of pretreatment modes
As shown by test results, the efficiency of distilling and extracting volatile oil in 3 modes is poor, so that a direct distillation and extraction mode is selected.
1.2.1.3 investigation of distillation time
Weighing 100g of litsea coreana and 50g of dried orange peel, uniformly mixing, taking three parts, respectively adding 5 times of water, respectively distilling and extracting for 2 hours, 3 hours and 4 hours, receiving distillate, washing the inner wall of a condensing tube and a volatile oil extractor with petroleum ether, combining the petroleum ether liquid and the oil-water liquid, extracting with petroleum ether three times, 15ml each time, combining the petroleum ether liquid, dehydrating and filtering with anhydrous sodium sulfate, washing a funnel with 10ml of petroleum ether, volatilizing petroleum ether to constant weight at low temperature, and weighing the weight of volatile oil to obtain the compound oil; collecting the volatile oil in another container. The results are shown in Table 3.
TABLE 3 investigation of distillation time
From the test results, the amount of volatile oil obtained by distillation for 2 hours is lower due to insufficient distillation; the efficiency of distillation for 3 hours is basically equivalent to that of distillation for 4 hours, and the distillation is determined to be 3 hours for saving time and energy.
1.2.2 Water extraction Process is preferred
1.2.2.1 factor level establishment
Research data show that factors influencing the water extraction effect mainly comprise water addition amount, extraction time and extraction times. The test is intended to conduct a 3-factor 3 level orthogonal investigation of these three main factors to optimize the optimal process parameters. The level of orthogonal test factors is shown in table 4:
TABLE 4 Water extraction Process orthogonal test factor level Table
1.2.2.2 evaluation index selection
The Chinese mahonia is a monarch drug in the prescription, and the main active ingredient berberine hydrochloride is a material basis for the prescription to exert curative effect, so that the extraction amount of the berberine hydrochloride can be used as one of evaluation indexes of an orthogonal test; in addition, the yield of the dry extract is also a conventional index for evaluating the extraction effect, and the dry extract directly influences the regulation of daily dose and single dose, so that the dry extract is also used as one of the orthogonal test evaluation indexes.
The test is to evaluate the orthogonal test by adopting a comprehensive evaluation method, and the evaluation scores are distributed as follows according to different influence degrees of each evaluation index on the extraction effect: the berberine hydrochloride is the effective component of the principal drug radix sophorae flavescentis in the prescription, the balance of the total extraction amount is defined as 70 minutes, the evaluation influence of the dry paste yield on the extraction effect is relatively small, and the balance is defined as 30 minutes.
Composite score = berberine hydrochloride extraction/maximum berberine hydrochloride extraction 70+ dry extract yield/maximum dry extract yield 30.
1.2.2.3 sample preparation
Weighing Chinese Mahonia, rhizoma corydalis, radix Cynanchi Paniculati and fructus evodiae according to the prescription, adding the residue of fructus Litseae Pungentis and pericarpium Citri Tangerinae after extracting volatile oil, performing extraction test according to the corresponding parameters of orthogonal test table (Table 5), filtering the medicinal liquid with 300 mesh filter cloth, concentrating the filtrate, and determining berberine hydrochloride extraction rate and dry extract yield. The results of the orthogonal tests are shown in Table 5 and the analysis of variance is shown in Table 6.
TABLE 5 Water extraction Process orthogonal test results
TABLE 6 Water extraction Process analysis of variance table
Note that: f0.05 (2, 2) =19.00;
as can be seen from the test results in Table 5 and the analysis of variance in Table 6, the primary and secondary actions of each factor are C > A > B; A. the C factors have obvious differences, the B factors have no obvious differences, and the A is the A factor 3 ＞A 2 ＞A 1 B among B factors 3 ＞B 2 ＞B 1 C among factors C 2 ＞C 3 ＞C 1 Therefore, the best process parameter of the analysis of variance result is A 3 B 3 C 2 . Due to A in A factor 2 And A 3 The extraction effect is close, and from the viewpoints of saving production cost and reducing energy, A is selected 2 As parameters, B is selected in compromise due to no significant difference of B factors 2 Is a parameter, thus the optimal process parameter is adjusted to be A 2 B 2 C 2 I.e. adding 6 times of water, decocting for 2 times, each time for 1 hour.
1.2.2.4 orthogonal validation test
Weighing the medicinal materials according to the prescription proportion, and weighing the medicinal materials according to A 2 B 2 C 2 And A 3 B 3 C 2 The parameters were subjected to extraction verification tests, the results of which are shown in Table 7.
TABLE 7 results of orthogonal test verification of Water extraction Process
The verification test result shows that A 2 B 2 C 2 The extraction effect of (A) and A 3 B 3 C 2 Has equivalent extraction effect, which is described in A 2 B 2 C 2 The process is reasonable and feasible, and finally the extraction process parameters are expressed as follows: decocting with water for 2 times and 6 times of water each time for 1 hr.
1.2.3 purification Process Studies
The common purification process of the traditional Chinese medicine extract is a water extraction and alcohol precipitation method, but the retention rate of a plurality of active ingredients is reduced when impurities are removed by the water extraction and alcohol precipitation method. Research data show that the ZTC clarifier purification method is an advanced impurity removal method, and has the greatest characteristics that the retention rate of active ingredients is high, the ZTC clarifier (ZTC clarifier B+ZTC clarifier A) selected in the experiment is added with the ZTC clarifier B firstly and then with the ZTC clarifier A, wherein the dosage ratio B: a=2:1. In order to optimize the purification process, the present invention compares the two purification methods by orthogonal experiments.
1.2.3.1 Water extraction and alcohol precipitation method
Factors influencing the water extraction and alcohol precipitation effect mainly comprise the specific gravity of the extract, the alcohol precipitation concentration and the standing time. The test is intended to conduct a 3-factor 3-level orthogonal investigation of these three main factors to optimize the optimal alcohol precipitation process parameters.
The test method comprises the following steps: according to the above optimum extraction process parameter test, extracting volatile oil from fructus Litseae and pericarpium Citri Tangerinae, standing the medicinal liquid, adding Mahonia, rhizoma corydalis, radix Cynanchi Paniculati and fructus evodiae into the residue, extracting, mixing the extractive solutions, dividing into 9 parts, and respectively performing alcohol precipitation test according to the requirement of orthogonal test table 9.
The evaluation method comprises the following steps: the test is to evaluate the orthogonal test by adopting a comprehensive evaluation method, takes the retention rate and the impurity removal rate of berberine hydrochloride as indexes, and evaluates the distribution of the scores as follows according to different influence degrees of the evaluation indexes on the purification effect: the retention rate of berberine hydrochloride is divided into 70 minutes, and the impurity removal rate is divided into 30 minutes.
Composite score = berberine hydrochloride retention/maximum berberine hydrochloride retention 70+ impurity removal rate/maximum impurity removal rate 30.
The level of orthogonal test factors is shown in Table 8, the test results are shown in Table 9, and the analysis of variance is shown in Table 10:
TABLE 8 orthogonal test factor level table for alcohol precipitation process
TABLE 9 results of orthogonal test of alcohol precipitation process
TABLE 10 analysis of variance table for alcohol precipitation process
Note that: f0.05 (2, 2) =19.00;
as can be seen from the test results in Table 9 and the analysis of variance in Table 10, the primary and secondary actions of each factor are B > A > C; A. the B factors have obvious differences, the C factors have no obvious differences, and the A factors are A 1 ＞A 2 ＞A 3 B among B factors 1 ＞B 2 ＞B 3 C among factors C 1 ＞C 3 ＞C 2 Therefore, the best process parameter of the analysis of variance result is A 1 B 1 C 1 . The extract is concentrated to a relative density of 1.05, ethanol is added to make the ethanol content 40%, and the mixture is left stand for 12 hours.
1.2.3.2ZTC clarifier purification process
Factors influencing the purification effect of the ZTC clarifier mainly comprise specific gravity of the extract, the dosage of the ZTC clarifier and the heat preservation temperature. The test is intended to take a 3-factor 3 level orthogonal investigation of these three main factors to optimize the optimal process parameters for decontamination.
The test method comprises the following steps: according to the above-mentioned optimum extraction technological parameter test, after extracting volatile oil from the fruit of litsea and dried orange peel, using the liquor for standby, adding Chinese mahonia, rhizoma corydalis, radix seu folium Desmodii Styracifolii and evodia rutaecarpa into the residue, continuously extracting, mixing the extract, dividing into 9 portions, and respectively making impurity-removing test according to the requirements of orthogonal test table 12.
The evaluation method comprises the following steps: extracting with water and precipitating with ethanol.
The level of orthogonal test factors is shown in Table 11, the test results are shown in Table 12, and the analysis of variance is shown in Table 13:
table 11ZTC clarifier impurity removal process orthogonal test factor level table
Table 12 results of orthogonal test of the process for removing impurities of ZTC clarifying agent
Table 13ZTC clarifying agent impurity removal process analysis of variance table
Note that: f0.05 (2, 2) =19.00;
as can be seen from the test results in Table 12 and the analysis of variance in Table 13, the primary and secondary actions of each factor are B > A > C; A. the B factors have obvious differences, the C factors have no obvious differences, and the A factors are A 2 ＞A 3 ＞A 1 B among B factors 2 ＞B 1 ＞B 3 C among factors C 3 ＞C 2 ＞C 1 Therefore, the best process parameter of the analysis of variance result is A 2 B 2 C 3 . Because the C factors have no significant difference, in order to reduce the energy consumption, C1 can be selected as the technological parameter, and finally the optimal technological parameter is determined as A 2 B 2 C 1 Concentrating the extractive solution to relative density of 1.10, adding 3% ZTC clarifier B solution, stirring, maintaining at 40deg.C for 30min, adding 1.5% ZTC clarifier A solution, stirring, and maintaining at 40deg.C for 20min.
1.2.3.3 two impurity removal Process optimal parameter contrast verification tests
And (3) verifying an alcohol precipitation impurity removal process: concentrating the extractive solution to relative density of 1.05, adding ethanol to ethanol content of 40%, and standing for 12 hr.
Clarifying agent impurity removal process verification: concentrating the extractive solution to relative density of 1.10, adding 3% ZTC clarifier B solution, stirring, maintaining at 40deg.C for 30min, adding 1.5% ZTC clarifier A solution, stirring, and maintaining at 40deg.C for 20min. The test results are shown in Table 14.
Table 14 results of two impurity removal process validations
The verification test result shows that the alcohol precipitation impurity removal process and the clarifying agent impurity removal process are stable in repeatability, compared with the two impurity removal methods, the clarifying agent impurity removal effect is more ideal, and the clarifying agent is obviously superior to the alcohol precipitation process in both the retention rate of active ingredients and the impurity removal rate, so that the clarifying agent impurity removal method is selected as the optimal impurity removal process.
1.2.4 concentration Process study
The common concentration methods of the water extract are two, one is normal pressure concentration and the other is reduced pressure concentration, and comparison tests are carried out on the two methods respectively.
Weighing the medicinal materials according to the prescription proportion, extracting according to the optimal technological parameters, filtering, dividing the filtrate into 2 parts, concentrating one part at normal pressure (-0.06 to-0.08 mpa,80 ℃), concentrating the other part at normal pressure to obtain thick extractum (the extractum is in a flag hanging phenomenon), and evaluating the concentration effect by taking the total amount of berberine hydrochloride, the color of the extractum and the concentration time in the thick extractum as indexes, wherein the result is shown in Table 15.
TABLE 15 results of concentration comparison tests
The test results show that the concentration mode has no obvious influence on the berberine hydrochloride content in the extract, the color of the extract is not obviously different, the reduced pressure concentration time is relatively short, the concentration mode selection diversity is considered, the concentration method mode is not explicitly specified in the process parameters, and a producer can make specific selection by combining workshop equipment.
2. Clinical efficacy verification
In order to verify the safety and efficacy of the formulations before and after the improvement process, we conducted clinical verification studies in this hospital (in the Zunyi market).
1. General data
200 cases of reflux esophagitis patients who are collected and treated by hospitals in the line of Izoy in 2021 month 1 to 2022 month 10 are selected, and all patients are subjected to clinical inquiry, biochemical laboratory examination, esophagoscopy and the like, so that the relevant diagnosis standard about reflux esophagitis in the "reflux esophagitis diagnosis and treatment guide" issued by the digestion endoscopic blood division of the Chinese medical society in 2003 is met.
The selected patients were divided into an observation group and a control group using a random number table method. 100 patients in the group were observed, 52 men and 48 women; age 25-64 (48.26+ -10.25); the course of the disease is 2 months to 4 years (average 1.28+/-0.24 years). 100 patients in the control group, 47 men and 53 women; age 24-69 (46.24 + -10.42); the course of the disease is 2 months to 4 years (average 1.13+/-0.19 years). The related clinical data of age, sex, disease course and the like of the patients in the group 2 are not greatly different (P is more than 0.05), and the patients are comparable.
2. Selection criteria
(1) Inclusion criteria: (1) reflux esophagitis has been diagnosed; (2) no other treatment regimen was applied prior to treatment in my hospital; (3) age > 18 years, a person with complete behavioural ability.
(2) Exclusion criteria: (1) is combined with mental disorder, mental illness or other patients who cannot normally communicate with each other; (2) patients with important organ dysfunction such as heart, liver, kidney, etc.; (3) patients with chronic diseases such as severe hypertension and diabetes are combined; (4) patients with malignant tumor diseases of digestive tract or surrounding tissues; (5) patients with application contraindications for the related drugs applied to the study; (6) women in gestation, parturient and lactation period; (7) patients who need surgical treatment such as perforation, severe hemorrhage, etc.
3. Therapeutic method
Group 2 patients were treated with internal medicine. The patient is guided to avoid holding weight and bending over during treatment, the patient wears loose clothes and trousers as much as possible, the head of the bed is lifted by 15cm during sleeping, and the patient does not eat food or eat tobacco or wine before sleeping for 6 hours. The domperidone is conventionally used for enhancing gastric motility, promoting gastric emptying, and the amoxicillin and other antibacterial medicines are used for anti-infective treatment. On the basis of conventional treatment, the patients in the observation group simultaneously apply Jiang Gongwei A granule preparation for oral administration 3 times a day. Patients in the control group adopt Jiang Gongwei A granule original process preparation for oral administration, and the dosage is 3 times per day. The 2 groups were treated continuously for 1 month.
4. Efficacy evaluation criteria
The patients have no clinical symptoms such as acid regurgitation, gastric burning, chest pain and the like, and the erosion or ulcer at the lesion part of the esophageal mucosa is obvious in effect after the patients are treated; the clinical symptoms are obviously improved after the treatment, and the erosion and ulcer areas of the lesion parts are reduced by more than 50% in the esophagoscope examination; the related clinical symptoms of the patients are not obviously improved after the treatment, or the reduction of the area of the lesion erosion and ulcer of the lesion part of the esophagoscope examination is less than 50 percent, which is ineffective. Total effective rate= (significant effect + effective)/total case number x 100%.
5. Statistical method
Data analysis was performed using SPSS 20.0 statistical software. Metering data to
Indicating that the comparison between groups adopts t test; count data is expressed as a rate (%), and χ is used for comparison between groups 2 And (5) checking. P < 0.05 is statistically significant for the differences.
6. Results
The therapeutic effect of the patients is shown in Table 19.
Table 19 comparative test results of the efficacy of different formulations (example/%)
Note that: p < 0.05 compared to the control group.
The clinical efficacy contrast test results show that the total effective rate of the clinical efficacy of the preparation produced by the Jiang Gongwei A granule adopting the improved process is improved by 9% compared with the original process, and the aim of improving quality and enhancing efficiency is achieved after the process is improved.
7. Adverse reactions
No adverse reactions occurred during the treatment of the patients.
While the invention has been described in detail in the foregoing general description, embodiments and experiments, it will be apparent to those skilled in the art that modifications or improvements can be made thereto. Accordingly, such modifications or improvements may be made without departing from the spirit of the invention and are intended to be within the scope of the invention as claimed.
Claims (10)
1. The ginger stomach-activating granule is characterized by comprising the following components in parts by weight: 180-220g of fructus alpiniae oxyphyllae, 180-220g of Chinese mahonia, 136-164g of rhizoma corydalis, 136-164g of radix cynanchi wilfordii, 94-106g of fructus evodiae and 94-106g of dried orange peel.
2. The Jiang Gongwei A granule as claimed in claim 1, which comprises the following components in parts by weight: 190-210g of fructus alpiniae oxyphyllae, 190-210g of Chinese mahonia, 143-157g of rhizoma corydalis, 143-157g of radix cynanchi wilfordii, 97-103g of fructus evodiae and 97-103g of dried orange peel.
3. The Jiang Gongwei A granule as claimed in claim 2, which comprises the following components in parts by weight: 200g of fructus litsea, 200g of Chinese mahonia, 150g of rhizoma corydalis, 150g of radix cynanchi wilfordii, 100g of fructus evodiae and 100g of dried orange peel.
4. A process for the preparation of Jiang Gongwei a granules as claimed in any one of claims 1 to 3, comprising the steps of:
(1) Extracting volatile oil: weighing fructus Litseae Pungentis and pericarpium Citri Tangerinae according to the proportion, adding 4-6 times of water, distilling and extracting for 2-4 hr, receiving distillate, standing to obtain volatile oil; filtering the water solution, and reserving filtrate;
(2) Water extraction: weighing Chinese mahonia, rhizoma corydalis, radix cynanchi wilfordii and fructus evodiae according to the prescription proportion, adding distilled fructus Litseae and pericarpium Citri Tangerinae residue, adding 4-8 times of water, decocting for 1-3 times, each time for 0.5-1.5h, filtering, and mixing filtrates;
(3) Purifying: concentrating the filtrate under reduced pressure to obtain fluid extract with relative density of 1.05-1.15, adding 2% -4% ZTC clarifier B solution into the fluid extract, stirring, maintaining at 40-60deg.C for 20-40min, then adding 1% -2% ZTC clarifier A solution, maintaining at 40-60deg.C for 20-40min, standing for 12-48 hr, filtering, and keeping filtrate for use;
(4) Concentrating: concentrating the filtrate under reduced pressure to obtain soft extract with relative density of 1.10-1.20;
(5) And (3) preparation molding: directly adding proper amount of soluble starch and 10g of aspartame into the thick paste, granulating, drying, spraying volatile oil, stewing thoroughly, and granulating to obtain 1000g of granules.
5. The method according to claim 4, wherein the step (1) is carried out by adding 5 times of water and distilling for 3 hours.
6. The method according to claim 4, wherein the step (2) is carried out by adding water and decocting for 2 times each for 1 hour, and adding 6 times of water each time.
7. The method according to claim 4, wherein the relative density in step (2) is preferably 1.10.
8. The preparation method according to claim 1, wherein 3% of ZTC clarifier B solution is added into the fluid extract in the step (3), stirred, heat-preserved for 30min at 40 ℃, then 1.5% of ZTC clarifier A solution is added, heat-preserved for 20min at 40 ℃, and left stand for 12h.
9. The method according to claim 1, wherein the conditions for the reduced pressure concentration in step (2) and step (4) are: the temperature is 75-85 ℃, and the pressure is-0.05 to-0.09 Mpa.
10. The method according to claim 9, wherein the conditions for the reduced pressure concentration in step (2) and step (4) are: the temperature is 80 ℃, and the pressure is-0.06 to-0.08 Mpa.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310285253.7A CN116270489B (en) | 2023-03-22 | 2023-03-22 | Ginger stomach-activating granule and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310285253.7A CN116270489B (en) | 2023-03-22 | 2023-03-22 | Ginger stomach-activating granule and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116270489A true CN116270489A (en) | 2023-06-23 |
| CN116270489B CN116270489B (en) | 2023-09-08 |
Family
ID=86816474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310285253.7A Active CN116270489B (en) | 2023-03-22 | 2023-03-22 | Ginger stomach-activating granule and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116270489B (en) |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1106678A (en) * | 1994-08-23 | 1995-08-16 | 路良宇 | Medicine for treatment of gastroenteritis and gastroenteritic ulcer and preparing process thereof |
| WO2001007034A1 (en) * | 1999-07-23 | 2001-02-01 | Colorado State University Research Foundation | Multidrug resistance pump inhibitors and uses thereof |
| CN1935212A (en) * | 2006-09-18 | 2007-03-28 | 贵州万胜药业有限责任公司 | Chinese medicine preparation for treating gastrosia |
| CN101011483A (en) * | 2007-02-14 | 2007-08-08 | 贵阳中医学院 | Chinese medicinal formulation for treating children's digestive system disease and its preparation method |
| CN101130013A (en) * | 2007-09-05 | 2008-02-27 | 米养素 | Traditional Chinese medicine composition for treating ulcer of stomach and duodenum, and method of preparing the same |
| CN101259259A (en) * | 2008-04-17 | 2008-09-10 | 陕西康惠制药有限公司 | Preparation of Chinese medicinal composition for treating chronic atrophic gastritis |
| CN101822799A (en) * | 2010-05-26 | 2010-09-08 | 成都晟铭医药科技有限公司 | Traditional Chinese medicine composition and preparation for treating diarrhea and preparation method thereof |
| CN104173969A (en) * | 2014-08-06 | 2014-12-03 | 江苏省中医药研究院 | Traditional Chinese medicine preparation for treating chronic gastritis caused by deficient cold of spleen and stomach and preparation method thereof |
| CN106563076A (en) * | 2016-08-03 | 2017-04-19 | 贵州大学 | Stomach disease treating medicine and production method thereof |
| CN108836961A (en) * | 2018-05-08 | 2018-11-20 | 贵州万胜药业有限责任公司 | A kind of Chinese medicine composition for treating stomachache |
| CN111840457A (en) * | 2020-07-22 | 2020-10-30 | 贵州中医药大学第一附属医院 | Liuhe antireflecting granule and preparation method thereof |
-
2023
- 2023-03-22 CN CN202310285253.7A patent/CN116270489B/en active Active
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1106678A (en) * | 1994-08-23 | 1995-08-16 | 路良宇 | Medicine for treatment of gastroenteritis and gastroenteritic ulcer and preparing process thereof |
| WO2001007034A1 (en) * | 1999-07-23 | 2001-02-01 | Colorado State University Research Foundation | Multidrug resistance pump inhibitors and uses thereof |
| CN1935212A (en) * | 2006-09-18 | 2007-03-28 | 贵州万胜药业有限责任公司 | Chinese medicine preparation for treating gastrosia |
| CN101011483A (en) * | 2007-02-14 | 2007-08-08 | 贵阳中医学院 | Chinese medicinal formulation for treating children's digestive system disease and its preparation method |
| CN101130013A (en) * | 2007-09-05 | 2008-02-27 | 米养素 | Traditional Chinese medicine composition for treating ulcer of stomach and duodenum, and method of preparing the same |
| CN101259259A (en) * | 2008-04-17 | 2008-09-10 | 陕西康惠制药有限公司 | Preparation of Chinese medicinal composition for treating chronic atrophic gastritis |
| CN101822799A (en) * | 2010-05-26 | 2010-09-08 | 成都晟铭医药科技有限公司 | Traditional Chinese medicine composition and preparation for treating diarrhea and preparation method thereof |
| CN104173969A (en) * | 2014-08-06 | 2014-12-03 | 江苏省中医药研究院 | Traditional Chinese medicine preparation for treating chronic gastritis caused by deficient cold of spleen and stomach and preparation method thereof |
| CN106563076A (en) * | 2016-08-03 | 2017-04-19 | 贵州大学 | Stomach disease treating medicine and production method thereof |
| CN108836961A (en) * | 2018-05-08 | 2018-11-20 | 贵州万胜药业有限责任公司 | A kind of Chinese medicine composition for treating stomachache |
| CN111840457A (en) * | 2020-07-22 | 2020-10-30 | 贵州中医药大学第一附属医院 | Liuhe antireflecting granule and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 李朝兴: "新一代纯天然澄清剂ZTC系列天然澄清剂", 离子交换与吸附, vol. 06, pages 565 - 568 * |
| 赵立春: "大果木姜子的化学成分研究", 《中国学术期刊（光盘版）》, no. 2007 * |
| 邱德文, 等: "贵州苗药大果木姜子研究及产业化", 贵阳中医学院学报, vol. 01, pages 48 - 51 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116270489B (en) | 2023-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103385993B (en) | Chinese medicine preparation for treating gastric ulcer and preparation method thereof | |
| CN102370727B (en) | Compound Chinese medicinal preparation of a kind of Cure of depression and preparation method thereof | |
| CN101780227B (en) | Traditional Chinese medicine composition for treating acute stroke and preparation method thereof | |
| CN116270489B (en) | Ginger stomach-activating granule and preparation method thereof | |
| CN108434239A (en) | Fill blood Antifatigue oral liquid and preparation method thereof | |
| CN101879272B (en) | Chinese medicinal compound for treating coronary heart diseases, preparation method and application thereof | |
| CN114028511B (en) | Traditional Chinese medicine composition for treating intractable gout and application thereof | |
| CN101829272B (en) | Traditional Chinese medicine composition for treating diabetes mellitus and preparation method thereof | |
| CN1048881C (en) | Medicine for curing tumour and preparation method thereof | |
| CN1739742A (en) | Chinese medicine capsule for treating cardiac and cerebral vascular diseases and its production process | |
| CN103536879B (en) | A kind of pharmaceutical composition and preparation method for the treatment of diabetes | |
| CN1712055A (en) | Chinese medicinal preparation (litholytic capsule) for treating urinific calculus | |
| CN103520684B (en) | Traditional Chinese medicine compound for reducing blood sugar | |
| CN1056752C (en) | Traditional Chinese medicine oral administration liquid for anti-cancer and its preparing method | |
| CN105853672A (en) | Composition with bowel-relaxing function and preparation method thereof | |
| CN101020026B (en) | Honeyed Guiqi ointment for enhancing body's resistance and its preparation | |
| CN105998752B (en) | A kind of Chinese medicine composition for the treatment of of vascular dementia | |
| CN1686194A (en) | Medicine for treating hemicrania and its preparation method | |
| CN109528891A (en) | A kind of Chinese materia medica preparation of prevention and treatment of coronary heart disease stable angina cordis | |
| CN1061256C (en) | Hypertension ointment for external use | |
| CN113018367B (en) | Traditional Chinese medicine composition for treating thin endometrial hypomenorrhea and preparation method and application thereof | |
| CN113262262B (en) | Traditional Chinese medicine preparation for treating phlegm-heat stasis type stable coronary heart disease and preparation method thereof | |
| CN102836315A (en) | Chinese medicinal composition for preventing and conditioning prognosis tumors and preparation method thereof | |
| CN102406790A (en) | Traditional Chinese medicine capsule for treating hyperplasia of mammary glands and preparation method thereof | |
| CN106728828A (en) | A kind of Chinese medicine preparation and its preparation technology for treating coronary heart disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |